A novel panel of blood-based microRNAs capable of discrimination between benign breast disease and breast cancer at early stages

References

• Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2016;388:1459–1544.
   Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–4434.
   PubMed Web of Science ®Google Scholar
• Lei J, Yang P, Zhang L, et al. Diagnostic accuracy of digital breast tomosynthesis versus digital mammography for benign and malignant lesions in breasts: a meta-analysis. Eur Radiol. 2014;24(3):595–602.
   PubMed Web of Science ®Google Scholar
• Inoue K, Fry EA. Novel molecular markers for breast cancer. Biomark Cancer. 2016;8:BIC.S38394.
   PubMedGoogle Scholar
• Danova M, Delfanti S, Manzoni M, et al. Tissue and soluble biomarkers in breast cancer and their applications: ready to use?. JNCI Monogr. 2011;2011(43):75–78.
   Google Scholar
• Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5–23.
   PubMed Web of Science ®Google Scholar
• Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Clin Oncol. 2007;25(33):5287–5312.
   Google Scholar
• Santangelo A, Tamanini A, Cabrini G, et al. Circulating microRNAs as emerging non-invasive biomarkers for gliomas. Ann Transl Med. 2017;5(13): 277-277.
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008;105(30):10513–10518.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524–15529.
   PubMed Web of Science ®Google Scholar
• Hébert SS, Horré K, Nicolaï L, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A. 2008;105(17):6415–6420.
   PubMed Web of Science ®Google Scholar
• Paul P, Chakraborty A, Sarkar D, et al. Interplay between miRNAs and human diseases. J Cell Physiol. 2007;233(3):2007–2018.
   Google Scholar
• Negrini M, Ferracin M, Sabbioni S, et al. MicroRNAs in human cancer: from research to therapy. J Cell Sci. 2007;120(11):1833–1840.
   PubMed Web of Science ®Google Scholar
• Fehlmann T, Kahraman M, Ludwig N, et al. Evaluating the use of circulating MicroRNA profiles for lung cancer detection in symptomatic patients. JAMA Oncol. 2020;6(5):714–723.
   PubMed Web of Science ®Google Scholar
• Hamam R, Ali AM, Alsaleh KA, et al. microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep. 2016;6(1). DOI:10.1038/srep25997
   PubMedGoogle Scholar
• Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009;106(11):4402–4407.
   PubMed Web of Science ®Google Scholar
• Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2011;91(4):579–587.
   PubMed Web of Science ®Google Scholar
• Wang G-K, Zhu J-Q, Zhang J-T, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31(6):659–666.
   PubMed Web of Science ®Google Scholar
• Livak K, Methods TS. undefined analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Elsevier; 2001;25(4):402–408.
   Google Scholar
• Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;3247:eaar3247.
   Google Scholar
• Vaidya VS, Ramirez V, Ichimura T, et al. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Physiol. 2006;290(2):F517–F529.
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol. 2004;15(1):24–30.
   PubMed Web of Science ®Google Scholar
• Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011;8(3):142–150.
   PubMed Web of Science ®Google Scholar
• Strissel PL, Schrauder MG, Strick R, et al. Circulating Micro-RNAs as potential blood-based markers for early stage breast cancer detection. 2012;7(1):e29770.
   Google Scholar
• Gyoba J, Shan S, Roa W, et al. Diagnosing lung cancers through examination of Micro-RNA biomarkers in blood, plasma, serum and sputum: a review and summary of current literature. Int J Mol Sci. 2016;17(494):494.
   PubMedGoogle Scholar
• Calderone HM, Westerhuis JJ, Winn ME, et al. Critical analysis of the potential for microRNA biomarkers in breast cancer management. 2015;7: 59–79.
   Google Scholar
• Baitsch L, Fuertes-Marraco SA, Legat A, et al. The three main stumbling blocks for anticancer T cells. Trends Immunol. 2012;33(7):364–372.
   PubMed Web of Science ®Google Scholar
• Leidinger P, Backes C, Dahmke IN, et al. What makes a blood cell based miRNA expression pattern disease specific? - A miRNome analysis of blood cell subsets in lung cancer patients and healthy controls. Oncotarget. 2014;5(19):9484.
   PubMedGoogle Scholar
• Backes C, Meese E, Keller A. Specific miRNA disease biomarkers in blood, serum and plasma: challenges and prospects. Mol Diagnosis Ther. 2016;206(20):509–518.
   Google Scholar
• Adhami M, Haghdoost AA, Sadeghi B, et al. Candidate miRNAs in human breast cancer biomarkers: a systematic review. Breast Cancer. 2018;25(2):198–205.
   PubMed Web of Science ®Google Scholar
• Git A, Dvinge H, Salmon-Divon M, et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA. 2010;16(5):991–1006.
   PubMed Web of Science ®Google Scholar
• Backes C, Leidinger P, Altmann G, et al. Influence of next-generation sequencing and storage conditions on miRNA patterns generated from PAXgene blood. Anal Chem. 2015;87(17):8910–8916.
   PubMed Web of Science ®Google Scholar
• Cuk K, Zucknick M, Madhavan D, et al. Plasma microRNA panel for minimally invasive detection of breast cancer. PLoS One. 2013;8(10):e76729.
   PubMed Web of Science ®Google Scholar
• Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers. 2013;34(3):163–169.
   PubMed Web of Science ®Google Scholar
• Zaleski M, Kobilay M, Schroeder L, et al. Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA. Oncotarget. 2018;9(32):22523–22536.
   PubMedGoogle Scholar
• Goncalves A, Sabatier R, Charafe-Jauffret E, et al. Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives. Bull Cancer. 2013;100:453–464.
   PubMed Web of Science ®Google Scholar
• Bahena‐Ocampo I, Espinosa M, Ceballos‐Cancino G, et al. miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation. EMBO Rep. 2016;17(5):648–658.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Xie H, et al. Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem. 2011;351(1–2):157–164.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang B, Wang HY, et al. Emerging role of MicroRNAs in mTOR signaling. Cell Mol Life Sci. 2017;74(14):2613–2625.
   PubMed Web of Science ®Google Scholar
• Li N, Miao Y, Shan Y, et al. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer. Cell Death Dis. 2017;8(5):e2796.
   PubMed Web of Science ®Google Scholar
• Li Q, Yao Y, Eades G, et al. Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer. Oncogene. 2014;33(20):2589–2600.
   PubMed Web of Science ®Google Scholar
• Wang F, Zheng Z, Guo J, et al. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586–593.
   PubMed Web of Science ®Google Scholar
• Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific MicroRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2):261–271.
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Conroy S, Ollberding N. Ethnic differences in serum adipokine and C-reactive protein levels: the multiethnic cohort. Int J Obesity. 2014;38(11):1416–1422.
   Google Scholar
• Brown M, Feairheller D, Thakkar S, et al. Racial differences in tumor necrosis factor-α-induced endothelial microparticles and interleukin-6 production. Vasc Heal Risk Managem. 2011;7:541.
   PubMedGoogle Scholar
• Nazmi A, Victora CG. Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health. 2007;7(1). DOI:10.1186/1471-2458-7-212
   PubMedGoogle Scholar
• Hu JJ, Urbanic JJ, Case LD, et al. journal of clinical oncology association between inflammatory Biomarker C-reactive protein and radiotherapy-induced early adverse skin reactions in a multiracial/ethnic breast cancer population. J Clin Oncol. 2018;36(24):2473–2482.
   PubMed Web of Science ®Google Scholar